Baxter reports positive HyQ phase III study data

Baxter has published its findings from a new phase III clinical trial of HyQ, its investigational combination immunoglobulin product for use in patients with primary immunodeficiencies.

The drug has been evaluated among 89 patients based in North America during the recent prospective open-label study, which assessed the effectiveness of HyQ in preventing infections, as well as a number of secondary endpoints.

It was discovered to provide strong efficacy and safety, as well as delivering encouraging performance in terms of pharmacokinetics, infusion volumes, intervals and rates compared to patients' previous intravenous immunoglobulin administration.

This data was presented to attendees of the recent American College of Allergy, Asthma and Immunology annual meeting and underlines the benefits of the drug, which has already been submitted for approval in the US and Europe.

Professor Hartmut Ehrlich, vice-president for research and development at Baxter's bioscience business, said: "These data support the potential clinical benefits of HyQ that, if approved, will make it an attractive therapeutic option for physicians and their patients with primary immunodeficiencies."

This comes after the firm reported positive clinical data for its new intravenous paediatric nutrition system Numeta earlier this month.